响应导游的聚乙二醇干扰素治疗慢性乙型肝炎

StephenW

Response Guided Treatment for Peginterferon in Chronic Hepatitis B

    P. Arends,
    H. L. A. Janssen


Abstract

Several baseline predictors that are associated with high response rates to PEG-IFN in CHB have been determined. Nonetheless, even patients with a high chance of achieving a response, are still at risk of non-response. Recently, a lot of effort has been made in discovering on-treatment predictors of response in order to provide solid stopping rules. In HBeAg positive patients the absence of a decline in HBsAg at week 12 provided the best stopping rule for HBV genotype A and D patients, whereas an HBsAg level > 20.000 IU/mL at week 12 was best for genotype B and C patients. For HBeAg negative patients, no HBsAg decline and less than 2 log HBV DNA decline at week 12 provided the best stopping rule, through all major HBV genotypes. Besides these stopping rules based on efficacy, pros and cons, including costs and side-effects of PEG-IFN based treatment, should always be weighed on an individual basis.

StephenW

高响应率，都与PEG-干扰素治疗慢性乙型肝炎的几个基线预测已经确定。然而，即使实现了响应的机会很高，患者仍处于无反应的风险。近日，已经取得了很多的努力，以提供坚实停止规则发现对治疗反应的预测。在HBeAg阳性患者下降的情况下在12周时HBsAg的HBV基因型A和D的患者提供了最好的阻止规则，而乙肝表面抗原水平>20.000 IU / mL的12周是最适合B，C基因型患者。对于周时HBeAg阴性患者，没有乙肝表面抗原下降不到2日志HBV DNA下降12提供了最好的停车规则，通过所有主要的HBV基因型。除了这些功效，利弊，包括成本和基于PEG-IFN治疗的副作用停止规则，应始终在个人基础上权衡.

咬牙硬挺

感谢分享